Enanta Pharmaceuticals, Inc. (ENTA)
ENTANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$11.37
-0.1050 (-0.92%) today
Regular session, Nov 10, 10:27 AM ET
- Market cap
- $331.01m
- P/E
- –
- EPS, last 4 quarters
- $-2.41
- Dividend yield
- –
- Day range
- $11.00 to $11.64
- 52-week range
- $10.05 to $17.15
- Average volume
- 262.7k
- Previous close
- $11.47
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $20.00, +76.0% from here
Earnings
next estimate $-0.8200Next report Nov 16, 2026
Sep 2025
+23.0%
Dec 2025
+22.2%
Mar 2026
+2.2%
Jun 2026
-81.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $15.13m | $18.61m | $17.16m | $14.36m |
| Gross profit | $15.13m | $18.61m | $17.16m | $14.36m |
| Operating income | -$18.39m | -$11.25m | -$11.85m | -$17.24m |
| Net income | -$18.70m | -$11.94m | -$13.09m | -$19.50m |
Last four quarters: revenue $65.26m, margin -96.9%, free cash flow -$36.94m
News
8 latest- Immatics (IMTX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 3 hours ago
- Kamada (KMDA) Surpasses Q3 Earnings EstimatesZacks · 1 day ago
- Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings EstimatesZacks · 6 days ago
- Unified Patent Court Rules Enanta Pharmaceuticals, Inc. Patent EP 4 051 265 InvalidFintel · Oct 29, 2026
- Enanta Pharmaceuticals, Inc. Announces Planned Retirement of CEO Jay R. Luly, Ph.D. by February 1, 2027Fintel · Oct 28, 2026
- Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue EstimatesZacks · Aug 5, 2026
- Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?Zacks · Jul 21, 2026
- Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?Zacks · Jun 24, 2026
The company
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta's clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company's immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- enanta.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.